Literature DB >> 7454387

The psychiatrist and the chronic pain patient: 172 anecdotes.

Robert G Large1.   

Abstract

The clinical experience of a psychiatrist working in a pain clinic is described. One hundred and seventy two patients were assessed over a 4-year period. The modal age was 45-54 years with a male : female ratio of 7 : 10. The model duration of pain was 1-5 years, the back being the commonest site. Depression was diagnosed in 30% of cases. PErsonality disorder, traumatic neurosis, anxiety, hysteria and drug dependence were the next most common diagnoses. Treatment was instituted in half of the patients seen and half of the treated patients improved or recovered. Drug withdrawal, EMG feedback and brief psychotherapy were associated with more improvement than pharmacotherapy or treatment at a psychiatric unit. The response to antidepressant medication was particularly disappointing and possible reasons for this are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7454387     DOI: 10.1016/0304-3959(80)90012-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

1.  Interdisciplinary treatment of chronic pain.

Authors:  M A Gardea; R J Gatchel
Journal:  Curr Rev Pain       Date:  2000

Review 2.  Psychological aspects of pain.

Authors:  R G Large
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

3.  Origin of chronic right upper quadrant pain.

Authors:  J G Kingham; A M Dawson
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

4.  Psychiatric aspects of chronic intractable pain.

Authors:  V K Varma; S K Chaturvedi; A Malhotra; P Chari
Journal:  Indian J Psychiatry       Date:  1983-07       Impact factor: 1.759

5.  Manifestation of Borderline Personality Symptomatology in Chronic Pain Patients Under Stress: An Understated and Exacerbated Consequence of the COVID-19 Crisis.

Authors:  Hannah Shapiro; Ronald J Kulich; Michael E Schatman
Journal:  J Pain Res       Date:  2020-06-15       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.